FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601043525> ?p ?o ?g. }

• W2601043525 endingPage "1149" @default.
• W2601043525 startingPage "1149" @default.
• W2601043525 abstract "Abstract Introduction : Daratumumab (DARA), a human CD38 IgG1κ monoclonal antibody, has demonstrated single agent efficacy while being highly tolerable as a monotherapy, and significant efficacy in combination with standard-of-care regimens in pts with multiple myeloma (MM) who have received ≥1 prior lines of therapy (Lokhorst HM. NEJM 2015, 373(13):1207-19; Lonial S. Lancet 2016, 387:1551-60;Palumbo A. NEJM 2016, in press; Dimopoulos MA. NEJM 2016, in press). DARA is currently administered as an intravenous (IV) infusion. Subcutaneous (SC) delivery of DARA is being tested in combination with the recombinant human hyaluronidase enzyme (rHuPH20) to facilitate systemic absorption of DARA after SC infusion into the abdominal wall. PAVO is the first study to assess the safety, pharmacokinetics, and efficacy of SC administration of DARA plus rHuPH20 (DARA-PH20) in pts with relapsed or refractory MM (RRMM). Methods : Pts had RRMM with ≥2 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD). Part 1 of the 2 part study enrolled sequential cohorts at 1200 mg and 1800 mg DARA dose levels to determine the recommended SC dose for Part 2. DARA-PH20 was administered in 4-week treatment cycles: QW for 8 weeks, Q2W for 16 weeks, and Q4W thereafter. DARA-PH20 was infused in 1200 mg doses in 60 mL over 20 min or 1800 mg in 90 mL over 30 min, via a syringe pump at rotating sites on the abdomen. Pre- and/or post-infusion medications included paracetamol, diphenhydramine, montelukast, and methylprednisolone. In part 2, pts will be randomized 1:1 to receive the recommended phase 2 dose (RP2D) of SC DARA-PH20 or IV DARA (16 mg/kg). The RP2D of DARA-PH20 will be selected based on a cumulative review of the pharmacokinetic and safety data obtained from part 1 and should achieve a maximum serum Ctrough during weekly dosing that is similar to or higher than that observed for the approved 16 mg/kg IV dose. Primary endpoints were Ctrough of DARA up to Cycle 3 Day 1 and safety. Secondary endpoints included overall response rate (ORR). Results : To date, 41 pts were treated in part 1 with SC DARA-PH20 at the 1200 mg (n=8) and 1800 mg (n=33) dose levels. Infusion related reactions (IRRs) were reported in 9/41 pts (22%) and were mostly grade 1/2 in severity including chills, fever, rigors, vomiting, itching, edema of the tongue, non-cardiac chest pain and wheezing. One pt developed grade 3 dyspnea and 1 pt required hospitalization due to fever and chills (both grade 2) after the first infusion. All IRRs developed during or within 6 hours of the first SC infusion and were controlled with antihistamine, corticosteroid, antiemetic, or bronchodilator treatment. No IRRs were reported with subsequent infusions. Overall, the adverse event profile of DARA-PH20 was consistent with that of IV DARA. Grade 3 or higher drug-related adverse events were reported in 5/41 (12%) pts including fatigue (2 pts), influenza, hypertension, dyspnea, and tumor lysis syndrome. SC administration of DARA-PH20 was well tolerated at the abdominal wall injection site with 3/41 (7%) pts reporting grade 1 erythema, induration, or burning sensation. Analysis showed a higher max Ctrough in the 1800 mg cohort in comparison to the max Ctrough achieved following IV DARA (16 mg/kg). In the 1200 mg cohort of 8 pts (median of 5 lines of prior therapy [range 2-10]; prior ASCT, 63%; PI refractory only, 0%; IMiD refractory only, 13%; double refractory to PI and IMiD, 63%) a 25% ORR was observed including 2 partial responses (PR). Median time to response was 14 (range 8-20) weeks. Among 17 response evaluable pts in the 1800 mg cohort with cycle 3 day 1 assessments (median of 4 prior lines of therapy [range 2-7]; prior ASCT, 76%; PI refractory only, 6%; IMiD refractory only, 12%; double refractory to PI and IMiD, 65%) a 41% ORR was observed consisting of 3 very good partial responses and 4 PRs. Median time to response was 4 (range 4-8) weeks. Conclusions : SC DARA-PH20 was well tolerated and achieved serum trough concentrations similar to or greater than IV DARA with a lower rate of IRRs compared to IV DARA over a significantly shorter infusion time. Preliminary data suggest that in this pt population SC DARA-PH20 may enable similar response rates to IV DARA monotherapy. The 1800 mg dose level of DARA-PH20 was selected as the RP2D for part 2 of the study. These early data support further study of SC DARA in clinical trials. Additional data on pts from part 1 will be presented at the meeting. Disclosures Usmani: Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; BioPharma: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Onyx: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pharmacyclics: Research Funding; Britsol-Myers Squibb: Consultancy, Research Funding; Skyline: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Array: Research Funding; Millenium: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Speakers Bureau. Mateos:Janssen, Celgene, Amgen, Takeda, BMS: Honoraria. Lokhorst:Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Genmab: Research Funding. Chari:Pharmacyclics: Research Funding; Janssen: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Amgen Inc.: Honoraria, Research Funding; Novartis: Consultancy, Research Funding; Array Biopharma: Consultancy, Research Funding. Kaufman:Celgene: Consultancy, Research Funding; Pharmacyclics: Consultancy; Novartis: Consultancy, Research Funding; Incyte: Consultancy. Moreau:Celgene: Honoraria; Bristol-Myers Squibb: Honoraria; Novartis: Honoraria; Amgen: Honoraria; Takeda: Honoraria; Janssen: Honoraria, Speakers Bureau. Oriol:Janssen: Honoraria, Other: Expert board committee; Amgen: Honoraria, Other: Expert board committee. Plesner:Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding. Hellemans:Janssen: Employment, Equity Ownership. Masterson:Janssen: Employment. Clemens:Janssen: Employment. Ahmadi:Janssen: Employment. Liu:Merck: Equity Ownership; Janssen: Employment; J&J: Equity Ownership. San-Miguel:Amgen: Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Onyx: Membership on an entity's Board of Directors or advisory committees; Millennium: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees." @default.
• W2601043525 created "2017-04-07" @default.
• W2601043525 creator A5006108161 @default.
• W2601043525 creator A5009378735 @default.
• W2601043525 creator A5009980783 @default.
• W2601043525 creator A5014436946 @default.
• W2601043525 creator A5027858059 @default.
• W2601043525 creator A5028707750 @default.
• W2601043525 creator A5029035458 @default.
• W2601043525 creator A5029159537 @default.
• W2601043525 creator A5054952877 @default.
• W2601043525 creator A5058429057 @default.
• W2601043525 creator A5063858836 @default.
• W2601043525 creator A5069449708 @default.
• W2601043525 creator A5070014603 @default.
• W2601043525 creator A5077388722 @default.
• W2601043525 creator A5077897003 @default.
• W2601043525 creator A5089163384 @default.
• W2601043525 date "2016-12-02" @default.
• W2601043525 modified "2023-10-18" @default.
• W2601043525 title "Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)" @default.
• W2601043525 doi "https://doi.org/10.1182/blood.v128.22.1149.1149" @default.
• W2601043525 hasPublicationYear "2016" @default.
• W2601043525 type Work @default.
• W2601043525 sameAs 2601043525 @default.
• W2601043525 citedByCount "20" @default.
• W2601043525 countsByYear W26010435252017 @default.
• W2601043525 countsByYear W26010435252018 @default.
• W2601043525 countsByYear W26010435252019 @default.
• W2601043525 countsByYear W26010435252020 @default.
• W2601043525 crossrefType "journal-article" @default.
• W2601043525 hasAuthorship W2601043525A5006108161 @default.
• W2601043525 hasAuthorship W2601043525A5009378735 @default.
• W2601043525 hasAuthorship W2601043525A5009980783 @default.
• W2601043525 hasAuthorship W2601043525A5014436946 @default.
• W2601043525 hasAuthorship W2601043525A5027858059 @default.
• W2601043525 hasAuthorship W2601043525A5028707750 @default.
• W2601043525 hasAuthorship W2601043525A5029035458 @default.
• W2601043525 hasAuthorship W2601043525A5029159537 @default.
• W2601043525 hasAuthorship W2601043525A5054952877 @default.
• W2601043525 hasAuthorship W2601043525A5058429057 @default.
• W2601043525 hasAuthorship W2601043525A5063858836 @default.
• W2601043525 hasAuthorship W2601043525A5069449708 @default.
• W2601043525 hasAuthorship W2601043525A5070014603 @default.
• W2601043525 hasAuthorship W2601043525A5077388722 @default.
• W2601043525 hasAuthorship W2601043525A5077897003 @default.
• W2601043525 hasAuthorship W2601043525A5089163384 @default.
• W2601043525 hasConcept C121332964 @default.
• W2601043525 hasConcept C126322002 @default.
• W2601043525 hasConcept C142424586 @default.
• W2601043525 hasConcept C143998085 @default.
• W2601043525 hasConcept C2776364478 @default.
• W2601043525 hasConcept C2777478702 @default.
• W2601043525 hasConcept C2778524551 @default.
• W2601043525 hasConcept C2781119759 @default.
• W2601043525 hasConcept C29730261 @default.
• W2601043525 hasConcept C31760486 @default.
• W2601043525 hasConcept C71924100 @default.
• W2601043525 hasConcept C87355193 @default.
• W2601043525 hasConceptScore W2601043525C121332964 @default.
• W2601043525 hasConceptScore W2601043525C126322002 @default.
• W2601043525 hasConceptScore W2601043525C142424586 @default.
• W2601043525 hasConceptScore W2601043525C143998085 @default.
• W2601043525 hasConceptScore W2601043525C2776364478 @default.
• W2601043525 hasConceptScore W2601043525C2777478702 @default.
• W2601043525 hasConceptScore W2601043525C2778524551 @default.
• W2601043525 hasConceptScore W2601043525C2781119759 @default.
• W2601043525 hasConceptScore W2601043525C29730261 @default.
• W2601043525 hasConceptScore W2601043525C31760486 @default.
• W2601043525 hasConceptScore W2601043525C71924100 @default.
• W2601043525 hasConceptScore W2601043525C87355193 @default.
• W2601043525 hasIssue "22" @default.
• W2601043525 hasLocation W26010435251 @default.
• W2601043525 hasOpenAccess W2601043525 @default.
• W2601043525 hasPrimaryLocation W26010435251 @default.
• W2601043525 hasRelatedWork W1197848312 @default.
• W2601043525 hasRelatedWork W2478188943 @default.
• W2601043525 hasRelatedWork W2608137803 @default.
• W2601043525 hasRelatedWork W2612089043 @default.
• W2601043525 hasRelatedWork W2920340622 @default.
• W2601043525 hasRelatedWork W2939294425 @default.
• W2601043525 hasRelatedWork W2980500792 @default.
• W2601043525 hasRelatedWork W3114717300 @default.
• W2601043525 hasRelatedWork W3167371147 @default.
• W2601043525 hasRelatedWork W3212164369 @default.
• W2601043525 hasVolume "128" @default.
• W2601043525 isParatext "false" @default.
• W2601043525 isRetracted "false" @default.
• W2601043525 magId "2601043525" @default.
• W2601043525 workType "article" @default.